Boston Scientific (NYSE: BSX) today announced the completion of its $3.7 billion acquisition of Axonics, Inc. (Nasdaq: AXNX).

Boston Scientific announced the acquisition in January, but the review timeline dragged on after the Federal Trade Commission ...

Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: AXNX), a ...

Boston Scientific, a Marlborough medical device manufacturer, has officially closed its acquisition of Axonics Inc. after entering into a purchase agreement in January.

The medical device maker has completed more than 40 acquisitions in recent years, helping turn it into one of the state’s ...

Boston Scientific Corporation's acquisition of Axonics, Inc. for $3.7 billion expands urology offerings with innovative ...

Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: ...

Boston Scientific produces less invasive medical ... interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare ...

Neuromodulation led the way with a 17% increase. Urology (10.3%) and Endoscopy (7.8%) followed. Outlook: Boston Scientific forecasts net sales growth for 2024 of approximately 16.5% on a reported ...

Boston Scientific Corporation reported 19.3% y ... which includes Urology, Endoscopy, and Neuromodulation, saw a growth of around 10% y/y. The Cardiovascular Segment, which includes Cardiology ...

Boston Scientific is keeping the ball rolling ... growth among medical surgical tools—including endoscopy, urology and neuromodulation—that totaled $1.479 billion. As a result, the company ...